Send us a text

On this week's Monday Morning Minute, Dr. Michael Koren and Kevin Geddings discuss the worry uncertainty brings in a changing government landscape and how this affects healthcare. They discuss the stress of not knowing what to expect with competing visions from the incoming administration and how the structure of clinical research trials provides consistency in uncertain times. The two talk about what may change with the second Trump administration, including research funding, healthcare dollars, and access to medicines like the GLP-1 inhibitors Maunjaro and Ozempic that help with diabetes, high blood pressure, and weight loss.

Koren's Three Key Takeaways:

• The new administration's health policies are unclear
• Access to GLP-1 inhibitor medications may change
• Clinical research provides consistent health monitoring

Recorded January 20, 2025

Be a part of advancing science by participating in clinical research.

Have a question for Dr. Koren? Email him at [email protected]

Listen on Spotify
Listen on Apple Podcasts
Watch on YouTube

Share with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.

Follow us on Social Media:
Facebook
Instagram
X (Formerly Twitter)
LinkedIn

Want to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.com

Music: Storyblocks - Corporate Inspired

Thank you for listening!